Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2009, Article ID 357093, 4 pages
http://dx.doi.org/10.1155/2009/357093
Research Article

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation

1Disciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, Brazil
2Laboratorio de Cytogenetica, da Disciplina de Hematologia, da Faculdade de Medicina, da Universidade de São Paulo, 05403-000 São Paulo, Brazil
3Fundação Pro-Sangue/ Hemocentro de São Paulo, 05403-000 São Paulo, Brazil

Received 2 July 2009; Accepted 14 August 2009

Academic Editor: Kazuhiko Yamada

Copyright © 2009 Monika Conchon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Rowley, “Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining,” Nature, vol. 243, pp. 290–293, 1973. View at Google Scholar
  2. C. M. Verfaillie, “Chronic myelogenous leukemia: too much or too little growth, or both?” Leukemia, vol. 12, pp. 136–138, 1998. View at Google Scholar
  3. B. J. Druker, S. Tamura, E. Buchdunger et al., “Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells,” Nature Medicine, vol. 2, no. 5, pp. 561–566, 1996. View at Google Scholar · View at Scopus
  4. P. le Coutre, L. Mologni, L. Cleris et al., “In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor,” Journal of the National Cancer Institute, vol. 91, pp. 163–168, 1999. View at Google Scholar
  5. B. J. Druker, C. L. Sawyers, H. Kantarjian et al., “Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome,” The New England Journal of Medicine, vol. 344, no. 14, pp. 1038–1042, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. B. J. Druker, M. Talpaz, D. J. Resta et al., “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia,” The New England Journal of Medicine, vol. 344, no. 14, pp. 1031–1037, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. H. M. Kantarjian, S. O'Brien, J. E. Cortes et al., “Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia,” Blood, vol. 100, no. 5, pp. 1590–1595, 2002. View at Google Scholar · View at Scopus
  8. B. J. Druker, F. Guilhot, S. G. O'Brien et al., “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia,” The New England Journal of Medicine, vol. 355, no. 23, pp. 2408–2417, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. Goldman, “Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007,” Bone Marrow Transplant, vol. 42, supplement 1, pp. S11–S13, 2008. View at Google Scholar
  10. H. J. Kolb, A. Schattenberg, J. M. Goldman et al., “Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients,” Blood, vol. 86, no. 5, pp. 2041–2050, 1995. View at Google Scholar · View at Scopus
  11. D. J. DeAngelo, E. P. Hochberg, E. P. Alyea et al., “Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease,” Clinical Cancer Research, vol. 10, no. 15, pp. 5065–5071, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. R. H. Collins Jr., O. Shpilberg, W. R. Drobyski et al., “Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation,” Journal of Clinical Oncology, vol. 15, no. 2, pp. 433–444, 1997. View at Google Scholar · View at Scopus
  13. G. Hess, D. Bunjes, W. Siegert et al., “Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7583–7593, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. E. Olavarria, C. Craddock, F. Dazzi et al., “Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation,” Blood, vol. 99, no. 10, pp. 3861–3862, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. H. M. Kantarjian, T. L. Smith, S. O'Brien, M. Beran, S. Pierce, and M. Talpaz, “Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-αtherapy. The Leukemia Service,” Annals of Internal Medicine, vol. 122, no. 4, pp. 254–261, 1995. View at Google Scholar · View at Scopus
  16. H. M. Kantarjian, S. O'Brien, T. L. Smith et al., “Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine,” Journal of Clinical Oncology, vol. 17, no. 1, pp. 284–292, 1999. View at Google Scholar · View at Scopus
  17. H. M. Kantarjian, S. O'Brien, J. E. Cortes et al., “Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis,” Cancer, vol. 97, no. 4, pp. 1033–1041, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. H. Kreyenberg, W. Holle, S. Mohrle, D. Niethammer, and P. Bader, “Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with flourescence detection: the Tuebingen experience,” Leukemia, vol. 17, no. 1, pp. 237–240, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. K. Merx, M. C. Müller, S. Kreil et al., “Early reduction of BCR-ABL mRNA transcript levels predict cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α,” Leukemia, vol. 16, no. 9, pp. 1579–1583, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. M. Michallet, M. L. Tanguy, G. Socie et al., “Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM),” British Journal of Haematology, vol. 108, no. 2, pp. 400–407, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. C. S. Higano, D. Chielens, W. Raskind et al., “Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation,” Blood, vol. 90, no. 7, pp. 2549–2554, 1997. View at Google Scholar · View at Scopus
  22. D. Gaziev, M. Galimberti, P. Polchi et al., “Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results,” Bone Marrow Transplantation, vol. 29, no. 1, pp. 1–8, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Palandri, M. Amabile, G. Rosti et al., “Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis,” Bone Marrow Transplantation, vol. 39, no. 3, pp. 189–191, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. Hayat, S. R. McCann, S. Langabeer, S. Irvine, M. F. McMullin, and E. Conneally, “Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation,” Haematologica, vol. 94, no. 2, pp. 296–298, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. L. Wang, K. Pearson, L. Pillitteri, J. E. Ferguson, and R. E. Clark, “Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia,” British Journal of Haematology, vol. 118, no. 3, pp. 771–777, 2002. View at Publisher · View at Google Scholar · View at Scopus